Wakix
What Wakix is used for
Wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.1).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Wakix
- Active substance
- pitolisant
- Disease area
- Narcolepsy
- Medicine group
- Other nervous system drugs
- ATC code
- N07XX11
- Marketing authorisation holder
- Bioprojet Pharma
- Authorised in the EU since
- 2016
Official information
In the USA
Same active substance: Wakix
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Wakix used for?
Wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.1).
What is the active substance in Wakix?
Wakix contains pitolisant.
Who makes Wakix?
The EU marketing authorisation holder is Bioprojet Pharma.
Is Wakix an orphan medicine?
Yes. Wakix is designated an orphan medicine in the EU, for a rare disease (Narcolepsy).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU